As phase three clinical trials for about 10 vaccines are currently underway, DBS Group Research believes that airline food caterer SATS will recover faster than expected.
The brokerage has upgraded the stock to a “buy” call from “hold” and raised its target price to $3.66 from $3.15 previously.
“We are advocating buying ahead of the recovery while valuations are attractive,” DBS analysts Alfie Yeo and Andy Sim write in note dated Oct 1.
